📊 INAB Key Takeaways
Is In8Bio, Inc.. (INAB) a Good Investment?
IN8BIO is a pre-revenue stage biotech company with strong balance sheet fundamentals (8.82x current ratio, zero debt, $27.1M cash) and approximately 2+ years of runway at current burn rates, but faces significant execution risk with no commercial revenue and substantial ongoing losses ($19.4M annually). Improving cost efficiency (74% EPS improvement YoY) suggests operational discipline, yet the lack of revenue and reliance on clinical development success warrant a cautious neutral stance pending evidence of meaningful commercialization.
IN8bio is pre-revenue with sustained operating and net losses, and profitability shows no improvement YoY despite an apparent EPS improvement likely driven by dilution. The balance sheet is strong (high cash, no debt, very high current ratio), providing ~2 years of runway at the current burn, but there is no evidence of revenue traction or improving unit economics. Until operating burn narrows or revenue begins, fundamentals warrant caution.
Why Buy In8Bio, Inc.. Stock? INAB Key Strengths
- Strong liquidity position with $27.1M cash representing 84% of total assets
- Zero debt burden with debt-to-equity ratio of 0.00x provides maximum financial flexibility
- Excellent short-term solvency with current ratio of 8.82x
- Year-over-year EPS improvement of 74% indicates improving cost structure despite ongoing losses
- Low liabilities ($4.7M) relative to assets create financial stability for R&D execution
- Robust liquidity and cash balance with no debt
- Very low liabilities and strong current ratio (8.8x)
- Clean capital structure supports near-term operations
INAB Stock Risks: In8Bio, Inc.. Investment Risks
- Pre-revenue stage with no commercial traction or product sales to date
- Substantial annual cash burn of $12.7M limits runway to approximately 2+ years at current rates
- Deeply negative profitability metrics (ROE -70.5%, ROA -60.2%) with no clear path to profitability
- Continued operating losses of $19.4M annually despite improving efficiency trends
- Inherent biotech development risk where clinical trial failures could rapidly deplete cash reserves
- Persistent operating losses with no revenue
- Dilution risk to fund ongoing R&D and trials
- Execution and regulatory uncertainty typical of clinical-stage biotech
Key Metrics to Watch
- Revenue generation timeline and first commercial product launch milestones
- Quarterly operating cash burn rate and updated cash runway projections
- Clinical trial progression and regulatory approval status for pipeline programs
- Cash balance trajectory and burn acceleration/deceleration trends
- Gross margin profile once revenue materializes to assess unit economics
- Operating cash flow (burn rate)
- Cash & equivalents / runway (months)
In8Bio, Inc.. (INAB) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 8.82x current ratio provides a solid financial cushion.
INAB Profit Margin, ROE & Profitability Analysis
INAB vs Healthcare Sector: How In8Bio, Inc.. Compares
How In8Bio, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is In8Bio, Inc.. Stock Overvalued? INAB Valuation Analysis 2026
Based on fundamental analysis, In8Bio, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
In8Bio, Inc.. Balance Sheet: INAB Debt, Cash & Liquidity
INAB Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: In8Bio, Inc..'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-17.05 indicates the company is currently unprofitable.
INAB Revenue Growth, EPS Growth & YoY Performance
In8Bio, Inc.. Dividends, Buybacks & Capital Allocation
INAB SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for In8Bio, Inc.. (CIK: 0001740279)
📋 Recent SEC Filings
❓ Frequently Asked Questions about INAB
What is the AI rating for INAB?
In8Bio, Inc.. (INAB) has a Combined AI Rating of SELL from Claude (HOLD) and ChatGPT (SELL) with 58% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are INAB's key strengths?
Claude: Strong liquidity position with $27.1M cash representing 84% of total assets. Zero debt burden with debt-to-equity ratio of 0.00x provides maximum financial flexibility. ChatGPT: Robust liquidity and cash balance with no debt. Very low liabilities and strong current ratio (8.8x).
What are the risks of investing in INAB?
Claude: Pre-revenue stage with no commercial traction or product sales to date. Substantial annual cash burn of $12.7M limits runway to approximately 2+ years at current rates. ChatGPT: Persistent operating losses with no revenue. Dilution risk to fund ongoing R&D and trials.
What is INAB's revenue and growth?
In8Bio, Inc.. reported revenue of N/A.
Does INAB pay dividends?
In8Bio, Inc.. does not currently pay dividends.
Where can I find INAB SEC filings?
Official SEC filings for In8Bio, Inc.. (CIK: 0001740279) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is INAB's EPS?
In8Bio, Inc.. has a diluted EPS of $-4.44.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is INAB a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, In8Bio, Inc.. has a SELL rating with 58% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is INAB stock overvalued or undervalued?
Valuation metrics for INAB: ROE of -70.5% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy INAB stock in 2026?
Our dual AI analysis gives In8Bio, Inc.. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is INAB's free cash flow?
In8Bio, Inc..'s operating cash flow is $-12.7M, with capital expenditures of $0.0.
How does INAB compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -70.5% (avg: 15%), current ratio 8.82 (avg: 2).